Ed Addison co-founded Cloud Pharmaceuticals in 2009. Addison is a serial entrepreneur who founded three previous ventures, two of which successfully merged with public companies. He has a unique and strong blend of in-depth business and technical experience in biotechnology and in information technology. Addison holds an MS in Biomedical Engineering from Johns Hopkins University and MBA from Duke University Fuqua School of Business, including a diploma in Duke’s Health Sector Management Program.
From 2000-2009, Addison focused on a series of ventures in the pharmaceutical and life sciences space. These included start-ups in the life sciences market, including BioFortis, a LIMS venture in Baltimore, and Inclinix, a CRO in Wilmington, NC, and TeraDisc, the predecessor of Cloud Pharmaceuticals, where he was named "Coastal Entrepreneur of the Year" in 2009. Addison has been working in drug discovery and development for over 12 years. As a life sciences business development professional, he has negotiated numerous licenses for therapeutics and technology. He spent the early part of his career in information technology.
Addison has been an adjunct professor for over 25 years. Previously he taught at Johns Hopkins University where he developed courses in bioinformatics and entrepreneurship. He was the co-founder and program director of the online MS degree in Bioinformatics for Johns Hopkins University's Whiting School. Addison received prior awards for entrepreneurship including "Entrepreneur of the Year" in 1994 by the Information Industry Association, and #51 on the National Fast 500, and Coastal Entrepreneur of the Year in 2009. He is the author of a book called Leveraging the Horizon about seed-stage technology ventures.
Comparative Business Models for In Silico Drug Discovery
Thursday, 29 September 2016 at 11:45
Add to Calendar ▼2016-09-29 11:45:002016-09-29 12:45:00Europe/LondonComparative Business Models for In Silico Drug DiscoveryIn Silico Drug Discovery and Predictive Toxicology 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
In Silico drug discovery is a young field only now showing seriously good results. Various business models have been applied – software licensing, drug discovery collaborations, pure services models, development of drugs for later license or full development, re-purposing of existing drugs. This panel will explore the trends, the intellectual property issues, the pros and cons of each model, and the receptivity of big pharma. The use of an asset-based LLC to hold, fund and share development of new drugs will be explored due to its explosive popularity.
Add to Calendar ▼2016-09-29 00:00:002016-09-30 00:00:00Europe/LondonIn Silico Drug Discovery and Predictive Toxicology 2016In Silico Drug Discovery and Predictive Toxicology 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2016-09-29 11:45:002016-09-29 12:45:00Europe/LondonComparative Business Models for In Silico Drug DiscoveryIn Silico Drug Discovery and Predictive Toxicology 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
